NCT00270413View on ClinicalTrials.gov

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Metastatic Breast Cancer
Interventions
DRUG

SU11248

sutent 50 mg daily 4w on 2w off

Trial Locations (13)

3000

UZ Leuven, Leuven

9000

UZ Gent, Ghent

Unknown

Imelda Bonheiden, Bonheiden

AZ st-jan brugge, Bruges

AZ VUB, Brussels

UCL, Brussels

Charleroi, Charleroi

ZOL, Hasselt

Liege sart-tilman, Liège

Namur st-elisabeth, Namur

St-Elisabeth Turnhout, Turnhout

AZ st-augustinus, Wilrijk

Mont-Godinne, Yvoir

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT00270413 - SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter